Memantine-Acrichine, 10 mg 84 pcs

A treatment for dementia. It is a non-competitive antagonist of glutamate NMDA-receptors (including in the substantia nigra), due to this it reduces excessive stimulating effect of cortical glutamate neurons on neostriatum, which develops on the background of insufficient dopamine release. By reducing the Ca²⁺ entry into neurons, it reduces the possibility of their destruction.

It has nootropic, cerebrovasodilatory, antihypoxic and psychostimulatory effects.

It improves impaired memory, increases ability to concentrate, reduces fatigue and symptoms of depression, reduces spasticity of skeletal muscles caused by brain disease or damage.

Indications

Active ingredient

Composition

Contents of the film coating:

(hypromellose – 4 mg,

Hyprolose (hydroxypropyl cellulose) – 1.552 mg,

talc – 1.568 mg,

titanium dioxide – 0.88 mg) or (dry film coating mixture, hypromellose (50%),

hyprolose (hydroxypropyl cellulose) (19.4%),

talc (19.6%),

titanium dioxide (11%)) – 8 mg.

How to take, the dosage

Interaction

When used concomitantly, memantine may reduce the effects of barbiturates and neuroleptics.

The effects of baclofen and dantrolene may be altered by memantine (doses may need to be adjusted for this combination).

The effects of levodopa, dopamine receptor agonists and anticholinergic agents are enhanced with concomitant use of NMDA-receptor antagonists.

Because memantine and amantadine are NMDA receptor antagonists, concomitant use should be avoided due to the risk of toxic effects.

Combinations of memantine with ketamine, dextromethorphan and phenytoin are also potentially toxic.

The same renal cation system is used for the transport of amantadine, cimetidine, ranitidine, quinidine and nicotine in the body, which may cause interaction of these drugs with memantine, resulting in increased plasma concentrations.

When used concomitantly, memantine can cause a decrease in the serum concentration of hydrochlorothiazide.

Concomitant use with warfarin and other indirect anticoagulants requires close monitoring of prothrombin time and INR.

Special Instructions

Caution should be exercised in patients with epilepsy, renal insufficiency, thyrotoxicosis, history of seizures, arterial hypertension, history of myocardial infarction, heart failure.

In case of impaired renal function, the dose of memantine should be reduced.

Features

Contraindications

Side effects

Nervous system disorders: dizziness, headache, somnolence, gait disturbance, confusion, hallucinations, convulsions, psychosis, hyperexcitability.

Digestive system disorders: constipation, vomiting, nausea, pancreatitis.

Cardiovascular system: increased BP, venous thrombosis, thromboembolism.

As to the body in general: fungal infections, general weakness, increased fatigue, allergic reactions.

Similarities